Discover exclusive news, ideas and insights from across the spectrum of healthcare innovation.

How will you advance healthcare?

Regular

The latest biotech venture capital news, updated weekly—tracking major funding rounds of $10M or more in 2026.

diving into funding dollar sign

Cure's Biotech Funding Tracker 2026

Data from 303 U.S. institutions tracks the full path from discovery to commercialization, revealing wide variation among the nation’s top biomedical players.

CII-Launch CII Ranks America's Biomedical Research Institutions Image

Introducing the Cure Innovation Index, Ranking Institutions That Turn Discovery Into Medicine

As part of the Cure Innovation Index, we surveyed 3,395 U.S. biomedical researchers to understand why discoveries aren't consistently commercialized and what the highest-performing institutions do differently.

CII-launch - What Makes an Institution Innovative? - Image

What Makes an Institution Innovative? A Cure Original Report

The data, the framework, and the decisions behind the first ranking of U.S. biomedical institutions on translational performance.

CII Prelaunch - Methodology How We Built the Cure Innovation Index - Image

Methodology How We Built the Cure Innovation Index - Image

Methodology: How We Built the Cure Innovation Index

CII-Launch - Glossary - Image

Glossary

How the Cure Innovation Index evaluates the science, infrastructure, and funding behind biomedical discovery.

CII-Launch - Research Capabilities Domain Explainer - Image

Best in Research Capabilities

How the Cure Innovation Index evaluates whether institutions can move scientific discoveries to market.

CII-Launch - Market Translation Domain Explainer  - Image

Best in Market Translation

How the Cure Innovation Index measures whether institutions prepare researchers to move from discovery to venture.

CII Best in Entrepreneurial Readiness Image

Entrepreneurial Readiness Domain Explainer

Best in Entrepreneurial Readiness 

Twenty universities ranked significantly higher in the Cure Innovation Index than their federal R&D spending would predict. Here's what they have in common.

CII-Launch - Institutions Punching Above Their Weight- Image

 Institutions Punching Above Their Weight

20 Universities Punching Above Their Weight in Biomedical Innovation

The powerhouses lead, but the Index reveals translational strength in unexpected places.

CII-Launch - Top States For Biomedical Research - Image

Top 10 States for Biomedical Innovation

As NIH funding shrinks and industry pulls back from early-stage science, universities are rethinking how discoveries move from the lab to the market.

State of the Biotech Innovation Ecosystem

Universities Face an Uncertain Future as Gap To Industry Keeps Growing

Most clinical trials fail, and the reasons extend far beyond the science. 

CII-Prelaunch - What's Standing Between a Promising Drug and the Patients Who Need It - Image

What's Standing Between a Promising Drug and the Patients Who Need It?

A Q&A with Peter Farmakis, CEO of 32 Biosciences, on building a company around the biology most microbiome startups missed, and what it takes to move from academic science to a fundable, clinical-stage therapeutic.

Cure Member Spotlight: Peter Farmakis Image

Cure Member Spotlight: Peter Farmakis

Federal grants are vanishing and VC dollars are concentrating at the top. For early-stage biotech founders, the path from lab to funding looks nothing like it did five years ago.

Who Is Funding the Science That's Too Early for Venture Capital?

The Bayh-Dole Act turned federally funded research into a commercialization pipeline that built American biotech. Forty-five years later, that pipeline faces a new set of political and financial pressures that could reshape how it works.

CII-Pre-Launch-How Universities Became the Engine of the Biotech Industry- Image

How Universities Became the Engine of the Biotech Industry

These companies are building procedure-driven devices with a clear path to FDA clearance and commercialization.

8 MedTech Startups to Watch in 2026

A Q&A with Larry Raoul James, CEO and President of MindLab, on why the opioid crisis was a drug design problem, and what it takes to build a next-generation pain therapeutic in a challenging category.

Cure Member Spotlight: Larry Raoul James Image

Cure Member Spotlight: Larry Raoul James

From ambient scribes to revenue cycle automation, these companies stand out for their solutions to healthcare's most persistent operational and clinical bottlenecks.

11 AI Companies Reshaping Healthcare Delivery and Clinical Workflows In 2026

As next-generation editing tools move from bench to bedside, these ten companies are leading the charge toward a new era of genetic medicine.

10 CRISPR Companies to Watch in 2026

Stem cell therapies are moving out of the lab and into the clinic, with early trials showing real signal and regulators opening faster paths to approval. These companies pushing the field toward standard care.

Stem Cell Companies to Watch in 2026 - Image Updated

10 Stem Cell Companies to Watch in 2026

A Q&A with Irene Rombel, Co-Founder and CEO of BioCurie, on why manufacturing—not discovery—is the real bottleneck in cell and gene therapy, and what it takes to build an AI-driven software company at the frontier of genomic medicine.

Cure Member Spotlight: Irene Rombel, PhD

The maternal health startup won $100,000 in equity investment from the Catalytic Impact Foundation at Cure's Power of X Summit.

DeepEcho Wins Second Annual CIF Prize in Women's Health

From early IP decisions to FDA strategy and investor negotiations, a biotech company’s legal needs shift quickly as it grows. Here’s how founders can build the right legal foundation, avoid common missteps, and bring in the right counsel at the right time.

The Legal Playbook for Building a Biotech Company, From Formation to Financing

Cure’s Power of X Summit, held on March 18–19, had a clear throughline: women’s health has moved from a long-standing thesis to a category with proof, traction, and capital behind it.

The Key Takeaways From Cure's Power of X: Women's Health Innovation Summit 2026

From AI-driven diagnostics to next-generation targeted therapies, these startups are redefining how cancer is understood, matched, and treated at the molecular level.

12 Biotech Companies Making Advances in Precision Oncology

The startup is using insights from the Cure by Deerfield Middle East Health Accelerator to refine its care model and expand access to pediatric endocrinology across new markets.

Virginia-Based EndoMD Builds Momentum After Third-Place Finish in Cure Accelerator

From self-amplifying RNA to programmable, cell-selective therapies, a new class of biotech companies is pushing mRNA beyond vaccines and into precision medicine across cancer, rare disease, and chronic conditions.

8 Biotech Companies Driving Breakthroughs in mRNA Vaccines

A Q&A with Oriana Zinani, PhD, Co-Founder and CEO of Applied PharmacoDynamics, on the science behind APD’s lead program for cocaine use disorder and what it takes to advance a first-in-class therapy in an area with enormous unmet need.


Cure Member Spotlight: Oriana Zinani, PhD

Moving a discovery from the lab to large-scale manufacturing requires far more than a handoff. Experts explain how technology transfer works in biotech and pharma, the different types of transfers, and why poor execution can delay commercialization.

Technology Transfer in Biotech and Pharma and the Process of Scaling New Medicines

Investment in women’s health is accelerating as founders build solutions that address longstanding gaps in care. These nine startups are developing technologies and care models that span fertility, maternal health, menopause, and healthy aging.

9 Women’s Health Startups to Watch in 2026 

Landing a job in biotech takes more than strong science credentials. Recruiters and founders explain what companies look for and how candidates can position themselves to break into the industry.

How to Get a Job in Biotech: A Career Guide for Scientists and Industry Entrants

A Q&A with Matt Lewis, CEO of Transformental, on why most AI transformations fail for human reasons, how healthcare organizations build “brain capital,” and what it takes to introduce AI responsibly in high-stakes environments.

Cure Member Spotlight: Matt Lewis Image

Cure Member Spotlight: Matt Lewis

After placing second at the Cure by Deerfield Middle East Health Accelerator in Qatar, NYC-based biotech VentriNaya is advancing its regenerative gene and cell therapy programs for cardiovascular disease while preparing for fundraising and regulatory milestones.

NYC-Based Gene and Cell Therapy Startup Builds Momentum After Runner-Up Finish in Cure Accelerator

Explore Seattle's most impactful biotech and life sciences companies, and learn why Washington continues to be one of the nation’s leading states for biopharma investment.

9 Biggest Biotech and Life Science Companies In Seattle

Business coach Chris Westfall explains why founders should resist making a formal mentorship ask too soon, and how to test for alignment, invite candid feedback, and build a relationship that sharpens strategy over time.

The Smarter Way to Find a Mentor for Your Startup, According to a Business Coach

After taking first place at The Cure by Deerfield Middle East Health Accelerator’s Demo Day, Atomistic Insights is establishing a presence in Qatar and exploring co-discovery partnerships, as it advances its physics-driven AI platform for drug development.

After Accelerator Win, Atlanta-Based AI Drug Discovery Startup Eyes Growth in Qatar

Ahead of this year's Catalytic Impact Foundation's pitch competition at the Power of X Summit, we checked in with last year's winners LunaJoy, Limax Biosciences, and Flourish Care, who have spent the past year scaling care delivery and advancing their missions.

Last Year’s CIF Impact Challenge Winners Put Funding to Work in Women’s Health

The Minneapolis-St. Paul region is experiencing a lot of growth in the biotech and life-sciences industry. Here are eight of the biggest biotech companies with connections to the area.

8 Biggest Biotech and Life Science Companies in Minneapolis and St. Paul

Nolan Townsend, CEO of Lexeo Therapeutics, shares candid lessons on how IPOs reshape investor relationships, disclosure strategy, and the day-to-day responsibilities of leading a public biotech company.

A Biotech CEO on How Going Public Reshapes the Role

Explore North Carolina’s most impactful biotech and life sciences companies, and learn why the state's Research Triangle Park (RTP), in particular, continues to be one of the nation’s leading hubs for biopharma investment and growth.

12 Biggest Biotech and Life Science Companies in North Carolina’s Research Triangle

For biotech startups, patient data is both a competitive edge and a legal risk. Experts explain how to collect, store, and use it responsibly without slowing growth.

Patient Data Is an Asset and a Liability—Here’s How to Avoid Costly Missteps

Explore the biggest biotech companies in the San Francisco Bay Area and see how the region’s mix of top research institutions, venture capital, and AI expertise keeps it at the center of global life sciences, even amid funding pressure and market recalibration.

11 Biggest Biotech Companies in the Bay Area

From AI-native care models to regulatory whiplash and new pressures around coverage and privacy, Out-of-Pocket Health founder Nikhil Krishnan lays out the forces expected to reshape biotech in the year ahead.

5 Ways Biotech Will Change in 2026, According to Nikhil Krishnan

Three biotech and digital health startups emerged as winners of Cure’s MEHA Demo Day, reflecting the region’s growing healthcare innovation ecosystem.

Cure’s Middle East Health Accelerator Picks Three Startups with Potential to Scale in the Region

Explore the biggest and most groundbreaking biotech companies in San Diego, and discover why the region remains one of the most vibrant life science hubs in the US.

11 Biggest Biotech Companies in San Diego

Lessons from Wandercraft CEO Matthieu Masselin on how risk, reimbursement, and regulation fundamentally change when scaling a healthcare company across Europe and the US.

The Key Differences Between Building a Healthcare Company in the US vs Europe

Patient focus groups can surface powerful insight or quietly mislead early decisions. Experts share tips for biotech teams on how to design and run focus groups that generate real, actionable input while respecting patient autonomy.

Patient Focus Groups Drive Better Research—Here's How to Get Real Insights

Salt Lake City’s biotech and life-sciences industry is experiencing a lot of growth. Here are eight of the biggest biotech companies with connections to the area.

7 Biggest Biotech Companies in Salt Lake City

Regulators and investors still want clean data, but patients want proof a therapy changes daily life. Here’s how early-stage biotech teams can choose endpoints that are measurable, meaningful, and feasible.

Patient-Centered Endpoints for Biotech Startups: Choosing Outcomes That Matter in the Real World

A Q&A with Karolyn Chamberlin, COO of Rarecells, on the science behind ISET, why whole circulating tumor cells matter for early cancer detection, and the challenge of translating decades of academic research into clinical impact.

Cure Member Spotlight: Karolyn Chamberlin

Clare Peeters, CBO and CFO of The New York Academy of Sciences, shares why a small set of financial metrics should stay top of mind for healthcare founders.

3 Key Financial Metrics That Decide the Fate of Your Company

Meet the latest founders, investors, and operators joining the Cure community, spanning biotech, medtech, AI, and healthcare services.

Meet the Founders, Investors, and Operators Joining the Cure Community

In a Q&A with Cure, Excelsior's CEO Mike Foley explains why small-molecule chemistry has become a bottleneck, and how the company is rebuilding it for automation, AI, and domestic drug manufacturing.

thumbnail excelsior spotlight mike foley phd headshot image

“Chemistry Needs a Reset”: Inside Excelsior’s Plan to Rebuild Small-Molecule Discovery

Experts outline how to assess fit, protect data quality, and decide where decentralization belongs in your clinical trial strategy.

Decentralized Trials 101: How to Decide if a DCT Model Fits Your Study and Keep Data Quality High

Patient advisory boards can inform high-stakes decisions, or erode trust if poorly designed. Experts share how to structure boards that deliver credible insights patients and investors take seriously.

How to Build a Patient Advisory Board That Actually Works in Biotech and Healthcare

As patients turn to AI for health answers, founders and healthcare builders are facing tough decisions around trust, regulation, escalation to human care, and how quickly to move.

ChatGPT Health Marks a Turning Point in Patient Expectations, Forcing Hard Choices for Innovators

Anne Fulenwider, co-founder and co-CEO of Alloy Helath, on why clear, jargon-free storytelling helps healthcare companies earn trust, traction, and scale. 

Storytelling Gives Healthcare Companies an Edge—Here's How to Use It Well Anne Fulenwider 16x9

Storytelling Gives Healthcare Companies an Edge—Here's How to Use It Well

Fewer blockbuster acquisitions, a surge of AI partnerships, and uneven regulatory signals defined this year’s JP Morgan Healthcare Conference.

JPM26 Recap: AI Takes Center Stage While Pharma Waits and Policy Signals Blur

As neuroscience matures, a new group of companies is pushing translation in CNS drug development, neurotechnology, diagnostics, and AI. We've rounded up eight startups that are doing just that in 2026.

8 Innovative Neuroscience Startups to Watch In 2026

These five healthcare-focused funds raised or launched capital in late 2025, with $4.5B to deploy across biotech, medtech, and digital health, including in the US.

5 Healthcare Funds Deploying $4.5 Billion Into Biotech and Medtech Right Now

Mathai Mammen, MD, Chairman, CEO, and President of Parabilis Medicines, shares how great biotech founders decide which diseases are worth pursuing, and why problem selection shapes everything that follows.

How Great Biotech Companies Decide Which Diseases to Take On

A Q&A with PolyCypher Health CEO Gilead Kedem, MD, on predicting chronic disease risk, rethinking polygenic scoring, and building preventive genomics for real-world care.

Cure Member Spotlight: Gilead Kedem, MD

From JPM Week and BIO to ASCO, AACR, and HIMSS, these biotech and life sciences events are where founders, investors, and industry leaders will connect and spot emerging trends in 2026.

13 Best Biotech and Life Sciences Conferences Taking Place In 2026

These biotech internship programs offer hands-on experience, mentorship, and real exposure to the U.S. life sciences ecosystem.

5 Notable Biotech Internships for Students and Recent Grads

From AI-driven drug discovery to next-generation diagnostics, these precision medicine startups are shaping how personalized care reaches patients in 2026.

9 Precision Medicine Startups to Watch in 2026

From fundraising and company building to regulation and market shifts, these biotech podcasts offer practical insights to keep you in the know.

10 Must-Listen Biotech Podcasts for Founders, Investors, and Operators

A look at 13 leading biotech venture capital firms backing life sciences startups, from early discovery through commercialization.

13 Leading Biotech Venture Capital Firms Shaping the Industry

A look at 13 startups and public companies advancing genetic medicines, cell-based therapies, and next-generation treatment platforms.

13 Cell and Gene Therapy Companies to Watch in 2026

Brianne Kimmel is redefining how women’s health gets funded. As founder and managing partner of WorkLife Ventures, she invests in female-led startups focused on making care more accessible, affordable, and aligned with women’s real-life needs.

Brianne Kimmel on Backing Female Founders Reshaping Women’s Health

A look at 11 companies using AI-driven platforms to reshape drug discovery, including generative models, computational chemistry, and data-centric biology.

11 Innovative Companies Using AI for Drug Discovery

Nell Smircina of Novastone Capital Advisors, and Tierney Saccavino-Payne of TSP Communications answer questions that are always top-of-mind for founders: from communicating setbacks to planning a raise.

Biotech Investor Relations Experts Answer Founders’ Most Asked Questions

In a candid conversation with Cure, Dr. Jay Bhattacharya talked about affordable manufacturing, gaps in today’s research system, rebuilding trust in science, and where he hopes entrepreneurs will step in.

NIH Chief Says Lowering Therapy Costs Is the Next Big Frontier for Entrepreneurs

A clear vision can set a biotech’s direction, but founders succeed when that vision adapts to new data, market shifts, and investor expectations. Greg Moss of Evommune explains why flexibility guides smarter strategy, stronger alignment, and better long term outcomes.

Why a Flexible Vision Is a Biotech Founder’s Strongest Asset

A list of the most promising anti-aging and longevity startups to watch in 2026, featuring companies developing epigenetic reprogramming, senolytics, AI-driven drug discovery, and next-generation cell rejuvenation therapies.

9 Anti-Aging and Longevity Startups to Watch in 2026

A practical guide for biotech founders on how to navigate the investor Q&A with clarity and confidence. Learn how to prepare, show traction, communicate your why, and present a plan investors can trust.

The Investor Q&A Is Crucial to Your Biotech Pitch—Here’s How to Nail It

CMS’ new payment rate for Eko Health’s AI-assisted cardiac exam signals growing federal support for AI in routine care, as more tools secure coverage and lawmakers push for broader reimbursement pathways.

Medicare Approves First Wave of AI Heart Screening Tools

Biotech lab experts explain how your early-stage startup can find affordable lab space, evaluate incubators, reduce upfront costs, and choose environments that support long-term growth.

Thumbnail Empty Laboratory DNA Computer Screen

The Biotech Founder’s Guide to Finding Affordable Lab Space That Supports Growth

Unicycive Therapeutics CEO Shalabh Gupta shares how to learn the leadership mindset that will keep teams aligned, keep you steady under pressure, and help you turn setbacks into momentum.

How Leadership Shapes a Biotech Startup, and the Mindset That Drives Success

AI tools now shape how investors, partners, and the public evaluate healthcare startups. Digital strategy leader Paul Herbert explains how AI interprets credibility and what founders can do to strengthen their visibility and trust signals.

SEO 2.0: How AI Shapes the Perception of Your Healthcare Startup

A tech-transfer leader from the University of Minnesota outlines six actionable tips to help you secure the right industry partner—from defining your needs to leveraging your network and TTO.

How to Find the Right Industry Partner for Your Research—Expert Tips That Actually Work

Explore the biggest biotech companies in Boston and Cambridge, their commercial pipelines, and why this life-science cluster remains the nation’s top center for innovation and investment.

13 Biggest Biotech Companies In Boston 

Biotech investor and Columbia Business School professor Dr. Aamir Rehman explains why the strongest early funding signal isn’t your science—it’s your founder’s equity. Here’s how it shapes investor trust.

The Funding Signal That Can Make or Break Your First VC Raise

Former FDA Commissioner Robert Califf, MD, outlines the biggest roadblocks facing biotech today. From trust and primary care gaps to regulatory instability—and where innovation is most needed.

Headshot Robert Califf MD

The Hard Truth About Biotech’s Future, According to Former FDA Chief Robert Califf

The FDA granted a second approval to Syndax’s menin inhibitor Revumenib, expanding its use to a larger genetic subset of acute myeloid leukemia and marking a rare back-to-back win nearly 20 years after the science first emerged.

Thumbnail laboratory pipette test tube research November 2025 - Image

A Targeted Leukemia Drug Just Won Two FDA Approvals in Under a Year

From funding wins to pipeline breakthroughs, these companies are the key players on New York's booming biotech scene.

New York Biotech Companies Hero Image

13 Biggest Biotech Companies in New York

Priyanka Jain, CEO and Co-Founder of Evvy, shares how cleanly dividing areas of ownership and expertise among the leadership team, and knowing exactly what not to build, helped the company move from idea to MVP, sell out its first product batch, and raise a $5M seed round.

The One Skill Early Founders Can’t Scale Without: Radical Ownership

FDA's top leadership just announced a fast-track approval pathway for personalized rare-disease therapies, built around clear biologic mechanisms, early patient improvement, and platform-based evidence from just a few treated cases.

FDA Signals New Fast Track for Personalized Rare-Disease Therapies

What's new

Blue

Explore the latest insights in healthcare innovation, featuring articles on cutting-edge research, trends, and success stories from industry leaders.

Introducing the Cure Innovation Index, Ranking Institutions That Turn Discovery Into Medicine

What Makes an Institution Innovative? A Cure Original Report

Your Home in NYC

Where Healthcare Innovators Connect

Accelerating Advances in Health

How will you advance healthcare?

What's new

Featured

Cure's Biotech Funding Tracker 2026

Join the Cure Community

Cure Email

This Week in Healthcare Innovation

Cure Innovation Original Report

What Makes an Institution Innovative

Cure Original Reports